Question · Q1 2026
Bhavesh Lodaya with BMO Capital Markets asked about Ashland's Life Sciences platform's exposure to the recently FDA-approved oral dose GLP-1 drug and the potential for demand pull from this medication.
Answer
Chair and CEO Guillermo Novo and SVP, Life Sciences and Intermediates, Alessandra Faccin Assis confirmed that oral GLP-1 and oral biologics represent a significant opportunity. Ashland's VP&D portfolio and tablet coatings, particularly high solids coatings like Aquarius Genesis, are relevant. They have multiple active projects with major pharma players, a pipeline of over 80 emerging opportunities, and plan to launch sodium caprate, a formulation enhancer, over the summer.
Ask follow-up questions
Fintool can predict
ASH's earnings beat/miss a week before the call
